Source: Annual Congress 2001 - Rare and unusual diseases or problems



Rating:

Share or cite this content

Citations should be made in the following way:
O. Ishimoto, R. Tazawa, M. Miki, M. Ebina, J. Saito, K. Nakata, T. Nukiwa (Sendai, Miyagi, Tokyo, Japan). Efficacy of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) in a Japanese female patient with pulmonary alveolar proteinosis (PAP). Eur Respir J 2001; 16: Suppl. 31, 1535

Member's Comments

No comment yet.

Related content which might interest you: Granulocyte-macrophage colony stimulating factor inhalation therapy as a treatment for pulmonary alveolar proteinosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis Source: Eur Respir J 2006; 27: 585-593 Year: 2006 Plasmapheresis for treatment of pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1220-1222 Year: 2009 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009 Association of genetic variations in the CSF2 and CSF3 genes with lung function in smoking-induced COPD Source: Eur Respir J 2008; 32: 25-34 Year: 2008 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Recovery of neutrophil apoptosis by ectoine: a new strategy against lung inflammation Source: Eur Respir J 2013; 41: 433-442 Year: 2013 Inhaled granulocyte–macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis Source: Eur Respir J, 51 (4) 1702127; 10.1183/13993003.02127-2017 Year: 2018 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Alveolar lipoproteinosis syndromes Source: Eur Respir Mon 2011; 54: 171-186 Year: 2011 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells Source: Eur Respir J 2001; 17: 1070-1077 Year: 2001 Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Inhibition of granulocyte activation by surfactant in a 2-yr-old female with meningococcus-induced ARDS Source: Eur Respir J 2002; 19: 776-779 Year: 2002 High serum granulocyte-colony stimulating factor characterises neutrophilic COPD exacerbations associated with dysbiosis Source: ERJ Open Res, 7 (3) 00836-2020; 10.1183/23120541.00836-2020 Year: 2021 Measurement of tumor necrosis factor (TNF)α, leukotriene B4 (LTB4), and interleukin 8 (IL8) in the exhaled breath condensate (EBC) in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Eur Respir J 2007; 30: Suppl. 51, 584s Year: 2007 Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007